Search For "global pharmaceutical company"
Glenmark receives one ANDA approval and two tentative ANDA approva
Updated : 2 weeks, 3 days ago IST
Mumbai (Maharashtra)[India], December 31 (ANI/PRNewswire): Glenmark Pharmaceuticals Limited (Glenmark), a research-led global pharmaceutical company has received final approval by the United States Food & Drug Administration (U.S. FDA) for Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg and 2
Read More
Glenmark becomes the first company to launch Remogliflozin + Vilda
Updated : 2 weeks, 5 days ago IST
Mumbai (Maharashtra) [India], December 29 . (ANI/PRNewswire): Glenmark Pharmaceuticals Limited (Glenmark), a research-led global pharmaceutical company has launched a fixed dose combination (FDC) of its novel, patent protected and globally researched Sodium Glucose Co-Transporter Inhibitor (
Read More
Glenmark appoints Dipankar Bhattacharjee to its Board of Directors
Updated : 5 months ago IST
Mumbai (Maharashtra) [India], Aug 17 (ANI/PRNewswire): Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, announced the appointment of Dipankar Bhattacharjee as Independent Non-Executive Director on the Board of the organization for a period of five years wit
Read More
Glenmark introduces higher strength (400 mg) of FabiFlu® to r
Updated : 5 months, 2 weeks ago IST
Mumbai (Maharashtra) [India] Aug 6 (ANI/PRNewswire): Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, today announced that it will introduce a 400 mg version of oral antiviral FabiFlu®, for the treatment of mild to moderate COVID-19 in India.
Read More
Glenmark responds to DCGI letter seeking clarification on Fabiflu
Updated : 6 months ago IST
Mumbai (Maharashtra) [India] July 21 (ANI/PRNewswire): In response to the DCGI letter seeking clarification on FabiFlu, Glenmark Pharmaceuticals Ltd, a research-led, integrated global pharmaceutical company, has responded back. Please click the link below, to access the response letter.
Read More
Glenmark commences 1000 patients Post Marketing Surveillance study
Updated : 6 months, 1 week ago IST
Mumbai (Maharashtra) [India], July 13 (ANI/PRNewswire): Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, has announced that it has commenced a Post Marketing Surveillance (PMS) study on FabiFlu® to closely monitor the efficacy and safety of the drug in
Read More
Zydus Cadila approaches DCGI to use hepatitis drug for COVID-19 cl
Updated : 8 months, 2 weeks ago IST
New Delhi [India], May 5 (ANI): The country's top drug regulator, Drug Controller General of India (DCGI), has received an application from Zydus Cadila, the leading global pharmaceutical company in India, to conduct clinical trial using antiviral drug 'Pegylated Interferon Alpha-2b' in adul
Read More
Zydus announces world's first drug for treatment of NASH
Updated : 10 months, 2 weeks ago IST
Ahmedabad (Gujarat) [India], Mar 5 (ANI): Global pharmaceutical company Zydus Cadila, on Thursday announced that the Drug Controller General of India (DCGI) has approved its new drug application (NDA) for Saroglitazar, a medicine for the treatment of a liver disease called Non-Cirrhotic Non-
Read More
Pfizer Inc and Mylan NV announce merger of Mylan with Upjohn
Updated : 1 year, 5 months ago IST
Mumbai (Maharashtra) [India], July 31 (ANI): Netherlands-based Mylan NV and US-based Pfizer Inc have announced a definitive agreement to combine Mylan with Upjohn, Pfizer's off-patent branded and generic established medicines business, creating a new global pharmaceutical company.
Read More
Cipla EU enters JV pact with Jiangsu Acebright Pharma of China
Updated : 1 year, 6 months ago IST
Mumbai (Maharashtra) [India], July 16 (ANI): Global pharmaceutical company Cipla announced a joint venture of its European subsidiary with Shanghai-based Jiangsu Acebright Pharmaceutical for manufacturing respiratory products in China.
Read More
Cipla Q4 net profit more than doubles to Rs 358 crore
Updated : 1 year, 8 months ago IST
Mumbai (Maharashtra) [India], May 22 (ANI): Global pharmaceutical company Cipla said on Wednesday its consolidated profit more than doubled to Rs 358 crore in the fourth quarter of 2018-19 from Rs 153 crore in the same quarter of previous year.
Read More